SILO · Silo Pharma, Inc.

This transaction represents a high-materiality strategic pivot for Silo Pharma, Inc., extending its business beyond pharmaceutical development into AI-powered software infrastructure. The acquisition of QwikAgents — a fully functional, web-based application marketed under that name — provides Silo Pharma with immediately deployable technology assets, including complete source and object code, documentation, and three branded domain names. The all-stock consideration of 2.1 million shares signals capital efficiency but also dilutes existing shareholders without cash outlay. Critically, the Agreement imposes strong protections on Silo Pharma: the Seller warrants exclusive, unencumbered ownership of both the software and domains, discloses its use of open-source components (specifically one unmodified LGPL binary), and commits to non-compete and non-challenge covenants regarding 'qwikagents'-branded assets — effectively securing long-term brand control. The six-month survival period for representations and warranties, coupled with indemnification capped at the value of the Purchase Price, balances risk allocation while limiting Silo Pharma’s exposure to latent defects or IP claims. Given the absence of financial metrics, revenue contribution, or integration plans in the filing, investors must await further disclosures to assess operational impact, scalability, or monetization strategy — but the acquisition clearly establishes a new technology vertical for the Company.